A nurse is assisting in the care of a client who has persistent depressive disorder. When reinforcing education to the client about their illness, which of the following statements should the nurse make?
"Persistent depressive disorder is a mild chronic form of depression."
"Persistent depressive disorder is characterized by delusions and hallucinations."
"Persistent depressive occurs shortly after taking or withdrawing from a substance."
"Persistent depressive is characterized by both manic and depressive episodes."
The Correct Answer is A
A. "Persistent depressive disorder is a mild chronic form of depression." PDD, previously known as dysthymia, is a long-lasting depressive condition with persistent low mood for at least two years. Symptoms are less severe than major depressive disorder but are continuous and can significantly impact daily life. While not as acute as major depression, PDD requires management through therapy, medication, and lifestyle modifications.
B. "Persistent depressive disorder is characterized by delusions and hallucinations." Psychotic features such as delusions and hallucinations are not typical of persistent depressive disorder (PDD). These symptoms are more commonly associated with major depressive disorder with psychotic features or schizophrenia. PDD primarily involves chronic low-grade depression rather than severe psychotic symptoms.
C. "Persistent depressive occurs shortly after taking or withdrawing from a substance." Substance-induced depressive disorder is a distinct diagnosis that results from drug use or withdrawal. Persistent depressive disorder is not caused by substance use but is a long-term mood disorder that lasts for at least two years. The symptoms are chronic and not directly linked to substance intake or withdrawal.
D. "Persistent depressive is characterized by both manic and depressive episodes." Bipolar disorder, not persistent depressive disorder, is characterized by alternating manic and depressive episodes. PDD involves a chronic, low-level depressive state without manic symptoms. Individuals with PDD may experience periods of worsening depression, but they do not exhibit the high-energy or euphoric states seen in bipolar disorder.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is C
Explanation
A. Lithium toxicity. The AIMS test does not assess lithium toxicity. Lithium toxicity is monitored through serum lithium levels and clinical symptoms such as tremors, nausea, confusion, and ataxia. Severe toxicity can lead to seizures, coma, and organ failure, requiring immediate intervention.
B. Alcohol withdrawal. The AIMS test does not assess alcohol withdrawal. Withdrawal symptoms include tremors, hallucinations, seizures, and autonomic instability. The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) is commonly used to assess symptom severity and guide treatment.
C. Tardive dyskinesia. The AIMS test is used to assess tardive dyskinesia, a movement disorder caused by long-term antipsychotic use. It evaluates involuntary movements of the face, tongue, and extremities, helping clinicians monitor progression and adjust medications to minimize symptoms.
D. Opiate withdrawal. The AIMS test does not assess opiate withdrawal. Symptoms include sweating, agitation, diarrhea, and muscle aches. The Clinical Opiate Withdrawal Scale (COWS) is typically used to assess withdrawal severity and guide opioid detoxification or replacement therapy.
Correct Answer is D
Explanation
A. Fluoxetine. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, anxiety, and obsessive-compulsive disorder. It does not alleviate tardive dyskinesia symptoms and is not indicated for managing extrapyramidal side effects.
B. Diphenhydramine. Diphenhydramine is an antihistamine that can help with acute dystonic reactions due to its anticholinergic effects, but it does not treat tardive dyskinesia. Long-term use may even worsen movement disorders.
C. Naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose. It has no effect on tardive dyskinesia, as this condition is related to prolonged dopamine receptor blockade rather than opioid activity.
D. Valbenazine. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor specifically approved for the treatment of tardive dyskinesia. It helps regulate dopamine release and reduces involuntary movements associated with the condition.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
